Head-To-Head Contrast: CRISPR Therapeutics (NASDAQ:CRSP) & Outlook Therapeutics (NASDAQ:OTLK)

Outlook Therapeutics (NASDAQ:OTLK) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Volatility and Risk

Outlook Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Valuation and Earnings

This table compares Outlook Therapeutics and CRISPR Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outlook Therapeutics	N/A	N/A	-$58.98 million	($11.41)	-0.65
CRISPR Therapeutics	$371.21 million	12.36	-$153.61 million	($2.72)	-19.86

Outlook Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Outlook Therapeutics and CRISPR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Outlook Therapeutics	N/A	-3,741.39%	-167.29%
CRISPR Therapeutics	N/A	-11.56%	-9.70%

Insider and Institutional Ownership

11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.3% of Outlook Therapeutics shares are held by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Outlook Therapeutics and CRISPR Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outlook Therapeutics	0	1	7	0	2.88
CRISPR Therapeutics	2	8	8	0	2.33

Outlook Therapeutics presently has a consensus price target of $46.43, suggesting a potential upside of 529.07%. CRISPR Therapeutics has a consensus price target of $75.71, suggesting a potential upside of 40.19%. Given Outlook Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Outlook Therapeutics is more favorable than CRISPR Therapeutics.

Summary

CRISPR Therapeutics beats Outlook Therapeutics on 7 of the 12 factors compared between the two stocks.

About Outlook Therapeutics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.